Jeff I agree with your view that " no way will initial reaction to patent loss be negligible "
But let's look on the positive side ...a win in this patent case.
A win gives AMRN monopoly power until Teva's entry ... ( 9.5yr from now ?)
What constrains AMRN from raising prices ...testing payers willingness to pay ?
The only thing reasons I can see to currently prevent AMRN from raising prices is .. fear of .political pressure and to reduce generics interest .
In a purely capitalistic world , the price of Vascepa would rise to the pt where it no longer was cost effective for insurers to use.
The ICER report places the cost to insurers of their R-IT population at around $5,000 a yr ....re vascularization , ER visits etc .
AMRN can double the cost to health providers for Vascepa ..from currently around $1,600 a yr ( will defer to HDG for the exact cost ) .....and the providers / insurers will still save money.
Just something to consider .
Now if Bernie's elected he would nationalize Amarin .....shareholders be dammed
Just kidding folks
Kiwi
News 
Market Data 
Discover 
AI
